AMGEN INC is 21.9x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($183.41 B vs $8.36 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | HALO | AMGN |
|---|---|---|
| Market cap | $8.36 B | $183.41 B |
| US-listed rank | #1040 | #79 |
| Revenue (latest FY) | $1.40B | $36.75B |
| Net income (latest FY) | $316.89M | $7.71B |
| Net margin | 22.7% | 21.0% |
| P/E (trailing FY) | 26.4 | 23.8 |
| SEC filings | 1,481 | 1,011 |
AMGEN INC is 21.9x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($183.41 B vs $8.36 B).
In their latest fiscal years, HALOZYME THERAPEUTICS, INC. reported $1.40B in revenue while AMGEN INC reported $36.75B.
Full pages: HALOZYME THERAPEUTICS, INC. and AMGEN INC, or browse the full rankings.